{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:32:02Z","timestamp":1792279922155,"version":"4.4.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["462165342"],"award-info":[{"award-number":["462165342"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["462165342"],"award-info":[{"award-number":["462165342"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["101191666"],"award-info":[{"award-number":["101191666"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["101191666"],"award-info":[{"award-number":["101191666"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is a critical need for precise analysis of virus\u2013host interactions to improve our understanding of infection processes. The integration of quantitative measurements with dynamic mathematical modeling has changed how we perceive cellular infection processes, offering profound insights into how viruses function at the cellular level. Here, we systematically review target cell-limited (TCL) ordinary differential equation (ODE) models related to SARS-CoV-2. We examine the spectrum of available models from basic TCL frameworks to more complex models incorporating antiviral treatments\u2014and highlight key findings, discuss strengths and limitations, and identify a shortage of comprehensive datasets, emphasizing structural identifiability issues.<\/jats:p>","DOI":"10.1038\/s44298-026-00183-8","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:00:23Z","timestamp":1773396023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ordinary differential equation models of SARS-CoV-2 replication dynamics and antiviral drug efficacies"],"prefix":"10.1038","volume":"4","author":[{"given":"Timon","family":"Kapischke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon T.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca D.","family":"Bertzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pfaender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kaderali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"183_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019Kovski","year":"2021","unstructured":"V\u2019Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"183_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","volume":"100","author":"VM Corman","year":"2018","unstructured":"Corman, V. M., Muth, D., Niemeyer, D. & Drosten, C. Hosts and sources of endemic human coronaviruses. Adv. Virus Res. 100, 163\u2013188 (2018).","journal-title":"Adv. Virus Res."},{"key":"183_CR3","doi-asserted-by":"publisher","unstructured":"Liu, D. X., Liang, J. Q. & Fung, T. S. In Encyclopedia of Virology (eds Bamford, D. H. & Zuckerman, M.) 428-440 (Academic Press, 2021) https:\/\/doi.org\/10.1016\/B978-0-12-809633-8.21501-X.","DOI":"10.1016\/B978-0-12-809633-8.21501-X"},{"key":"183_CR4","doi-asserted-by":"crossref","unstructured":"Westhoven, S. et al. From zoonotic spillover to endemicity: the broad determinants of human coronavirus tropism. mBio 16, e0243725 (2025).","DOI":"10.1128\/mbio.02437-25"},{"key":"183_CR5","unstructured":"Ho, M.-S. In Tropical Infectious Diseases: Principles, Pathogens and Practice, (eds Guerrant, R. L., Walker, D. H. & Weller, P. F.) Ch. 59 (Saunders, 2011)."},{"key":"183_CR6","first-page":"1960","volume":"381","author":"The Lancet","year":"2013","unstructured":"The Lancet MERS-CoV: a global challenge. Lancet 381, 1960 (2013).","journal-title":"Lancet"},{"key":"183_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"183_CR8","unstructured":"WHO. WHO COVID-19. https:\/\/data.who.int\/dashboards\/covid19\/ (2025)."},{"key":"183_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41579-023-01003-z","volume":"22","author":"S Steiner","year":"2024","unstructured":"Steiner, S. et al. SARS-CoV-2 biology and host interactions. Nat. Rev. Microbiol. 22, 206\u2013225 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"183_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12700","volume":"285","author":"AS Perelson","year":"2018","unstructured":"Perelson, A. S. & Ribeiro, R. M. Introduction to modeling viral infections and immunity. Immunol. Rev. 285, 5\u20138 (2018).","journal-title":"Immunol. Rev."},{"key":"183_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41592-024-02265-y","volume":"21","author":"AM Smith","year":"2024","unstructured":"Smith, A. M. Decoding immune kinetics: unveiling secrets using custom-built mathematical models. Nat. Methods 21, 744\u2013747 (2024).","journal-title":"Nat. Methods"},{"key":"183_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1152-1","volume":"16","author":"JD Munday","year":"2018","unstructured":"Munday, J. D., van Hoek, A. J., Edmunds, W. J. & Atkins, K. E. Quantifying the impact of social groups and vaccination on inequalities in infectious diseases using a mathematical model. BMC Med. 16, 162 (2018).","journal-title":"BMC Med."},{"key":"183_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jtbi.2018.03.025","volume":"447","author":"F Fatehi Chenar","year":"2018","unstructured":"Fatehi Chenar, F., Kyrychko, Y. N. & Blyuss, K. B. Mathematical model of immune response to hepatitis B. J. Theor. Biol. 447, 98\u2013110 (2018).","journal-title":"J. Theor. Biol."},{"key":"183_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-01926-5","volume":"19","author":"M Yechezkel","year":"2021","unstructured":"Yechezkel, M., Ndeffo Mbah, M. L. & Yamin, D. Optimizing antiviral treatment for seasonal influenza in the USA: a mathematical modeling analysis. BMC Med. 19, 54 (2021).","journal-title":"BMC Med."},{"key":"183_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev-virology-110615-042249","volume":"3","author":"F Graw","year":"2016","unstructured":"Graw, F. & Perelson, A. S. Modeling viral spread. Ann. Rev. Virol. 3, 555\u2013572 (2016).","journal-title":"Ann. Rev. Virol."},{"key":"183_CR16","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/1873-3468.12095","volume":"590","author":"P Kumberger","year":"2016","unstructured":"Kumberger, P., Frey, F., Schwarz, U. S. & Graw, F. Multiscale modeling of virus replication and spread. FEBS Lett. 590, 1972\u20131986 (2016).","journal-title":"FEBS Lett."},{"key":"183_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3389\/fmicb.2018.01546","volume":"9","author":"C Zitzmann","year":"2018","unstructured":"Zitzmann, C. & Kaderali, L. Mathematical analysis of viral replication dynamics and antiviral treatment strategies: from basic models to age-based multi-scale modeling. Front. Microbiol. 9, 1546 (2018).","journal-title":"Front. Microbiol."},{"key":"183_CR18","doi-asserted-by":"publisher","first-page":"e1007705","DOI":"10.1371\/journal.pcbi.1007705","volume":"16","author":"C Quirouette","year":"2020","unstructured":"Quirouette, C., Younis, N. P., Reddy, M. B. & Beauchemin, C. A. A. A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. PLoS Comput. Biol. 16, e1007705 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"183_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","volume":"114","author":"AS Perelson","year":"1993","unstructured":"Perelson, A. S., Kirschner, D. E. & De Boer, R. Dynamics of HIV infection of CD4+ T cells. Math. Biosci. 114, 81\u2013125 (1993).","journal-title":"Math. Biosci."},{"key":"183_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/373117a0","volume":"373","author":"X Wei","year":"1995","unstructured":"Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117\u2013122 (1995).","journal-title":"Nature"},{"key":"183_CR21","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","volume":"93","author":"MA Nowak","year":"1996","unstructured":"Nowak, M. A. et al. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93, 4398\u20134402 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"183_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.272.5258.74","volume":"272","author":"MA Nowak","year":"1996","unstructured":"Nowak, M. A. & Bangham, C. R. Population dynamics of immune responses to persistent viruses. Science 272, 74\u201379 (1996).","journal-title":"Science"},{"key":"183_CR23","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1128\/JVI.01623-05","volume":"80","author":"P Baccam","year":"2006","unstructured":"Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590\u20137599 (2006).","journal-title":"J. Virol."},{"key":"183_CR24","doi-asserted-by":"publisher","first-page":"e1011356","DOI":"10.1371\/journal.pcbi.1011356","volume":"19","author":"B Raach","year":"2023","unstructured":"Raach, B. et al. Influence of cell type specific infectivity and tissue composition on SARS-CoV-2 infection dynamics within human airway epithelium. PLoS Comput. Biol. 19, e1011356 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"183_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18683-x","volume":"12","author":"SM Ciupe","year":"2022","unstructured":"Ciupe, S. M. & Tuncer, N. Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans. Sci. Rep. 12, 14637 (2022).","journal-title":"Sci. Rep."},{"key":"183_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2020.108438","volume":"328","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Modeling the viral dynamics of SARS-CoV-2 infection. Math. Biosci. 328, 108438 (2020).","journal-title":"Math. Biosci."},{"key":"183_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1021\/acsptsci.0c00183","volume":"4","author":"P Dogra","year":"2021","unstructured":"Dogra, P. et al. Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model. ACS Pharmacol. Transl. Sci. 4, 248\u2013265 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"183_CR28","doi-asserted-by":"publisher","first-page":"e1011437","DOI":"10.1371\/journal.pcbi.1011437","volume":"20","author":"C Zitzmann","year":"2024","unstructured":"Zitzmann, C., Ke, R., Ribeiro, R. M. & Perelson, A. S. How robust are estimates of key parameters in standard viral dynamic models?. PLoS Comput. Biol. 20, e1011437 (2024).","journal-title":"PLoS Comput. Biol."},{"key":"183_CR29","doi-asserted-by":"publisher","first-page":"111449","DOI":"10.1016\/j.jtbi.2023.111449","volume":"564","author":"CS Korosec","year":"2023","unstructured":"Korosec, C. S. et al. Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: parameter estimates, identifiability, sensitivity and the eclipse phase profile. J. Theor. Biol. 564, 111449 (2023).","journal-title":"J. Theor. Biol."},{"key":"183_CR30","first-page":"147","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. 21, 147\u2013161 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"183_CR31","doi-asserted-by":"publisher","first-page":"e3001128","DOI":"10.1371\/journal.pbio.3001128","volume":"19","author":"KS Kim","year":"2021","unstructured":"Kim, K. S. et al. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biol. 19, e3001128 (2021).","journal-title":"PLoS Biol."},{"key":"183_CR32","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2023.0187","volume":"20","author":"CP McCormack","year":"2023","unstructured":"McCormack, C. P. et al. Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types. J. R. Soc. Interface 20, 20230187 (2023).","journal-title":"J. R. Soc. Interface"},{"key":"183_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09572-x","volume":"24","author":"MW Tan","year":"2024","unstructured":"Tan, M. W. et al. Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories. BMC Infect. Dis. 24, 654 (2024).","journal-title":"BMC Infect. Dis."},{"key":"183_CR34","doi-asserted-by":"publisher","first-page":"110895","DOI":"10.1016\/j.jtbi.2021.110895","volume":"531","author":"V Bernhauerova","year":"2021","unstructured":"Bernhauerova, V., Lisowski, B., Rezelj, V. V. & Vignuzzi, M. Mathematical modelling of SARS-CoV-2 infection of human and animal host cells reveals differences in the infection rates and delays in viral particle production by infected cells. J. Theor. Biol. 531, 110895 (2021).","journal-title":"J. Theor. Biol."},{"key":"183_CR35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41564-022-01105-z","volume":"7","author":"R Ke","year":"2022","unstructured":"Ke, R. et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat. Microbiol. 7, 640\u2013652 (2022).","journal-title":"Nat. Microbiol."},{"key":"183_CR36","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/psp4.13022","volume":"12","author":"S Zhang","year":"2023","unstructured":"Zhang, S., Agyeman, A. A., Hadjichrysanthou, C. & Standing, J. F. SARS-CoV-2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy. CPT Pharmacometrics Syst. Pharmacol. 12, 1450\u20131460 (2023).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"183_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1487066","volume":"16","author":"D Hodgson","year":"2025","unstructured":"Hodgson, D. et al. Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines. Front. Immunol. 16, 1487066 (2025).","journal-title":"Front. Immunol."},{"key":"183_CR38","doi-asserted-by":"crossref","unstructured":"N\u00e9ant, N. et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc. Natl. Acad. Sci. USA 118, e2017962118 (2021).","DOI":"10.1073\/pnas.2017962118"},{"key":"183_CR39","doi-asserted-by":"publisher","first-page":"109178","DOI":"10.1016\/j.mbs.2024.109178","volume":"371","author":"L Schuh","year":"2024","unstructured":"Schuh, L., Markov, P. V., Veliov, V. M. & Stilianakis, N. I. A mathematical model for the within-host (re)infection dynamics of SARS-CoV-2. Math. Biosci. 371, 109178 (2024).","journal-title":"Math. Biosci."},{"key":"183_CR40","doi-asserted-by":"publisher","first-page":"e08207","DOI":"10.1016\/j.heliyon.2021.e08207","volume":"7","author":"M Odaka","year":"2021","unstructured":"Odaka, M. & Inoue, K. Modeling viral dynamics in SARS-CoV-2 infection based on differential equations and numerical analysis. Heliyon 7, e08207 (2021).","journal-title":"Heliyon"},{"key":"183_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406303121","volume":"121","author":"SA Iyaniwura","year":"2024","unstructured":"Iyaniwura, S. A. et al. The kinetics of SARS-CoV-2 infection based on a human challenge study. Proc. Natl. Acad. Sci. USA 121, e2406303121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"183_CR42","doi-asserted-by":"crossref","unstructured":"Owens, K., Esmaeili, S. & Schiffer, J. T. Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses. JCI Insight 9, e176286 (2024).","DOI":"10.1172\/jci.insight.176286"},{"key":"183_CR43","doi-asserted-by":"publisher","first-page":"210090","DOI":"10.1098\/rsos.210090","volume":"8","author":"RN Leander","year":"2021","unstructured":"Leander, R. N., Wu, Y., Ding, W., Nelson, D. E. & Sinkala, Z. A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium. R. Soc. Open Sci. 8, 210090 (2021).","journal-title":"R. Soc. Open Sci."},{"key":"183_CR44","doi-asserted-by":"crossref","unstructured":"Ke, R., Zitzmann, C., Ho, D. D., Ribeiro, R. M. & Perelson, A. S. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person\u2019s infectiousness. Proc. Natl. Acad. Sci. USA 118, e2111477118 (2021).","DOI":"10.1073\/pnas.2111477118"},{"key":"183_CR45","doi-asserted-by":"publisher","first-page":"e0050922","DOI":"10.1128\/jvi.00509-22","volume":"96","author":"J Lin","year":"2022","unstructured":"Lin, J. et al. Longitudinal assessment of SARS-CoV-2-specific T cell cytokine-producing responses for 1 year reveals persistence of multicytokine proliferative responses, with greater immunity associated with disease severity. J. Virol. 96, e0050922 (2022).","journal-title":"J. Virol."},{"key":"183_CR46","doi-asserted-by":"publisher","first-page":"e1011383","DOI":"10.1371\/journal.pcbi.1011383","volume":"19","author":"Z Zhou","year":"2023","unstructured":"Zhou, Z. et al. Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients. PLoS Comput. Biol. 19, e1011383 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"183_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.639423","volume":"8","author":"RF Reis","year":"2021","unstructured":"Reis, R. F. et al. A validated mathematical model of the cytokine release syndrome in severe COVID-19. Front. Mol. Biosci. 8, 639423 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"183_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11538-025-01442-0","volume":"87","author":"L Fan","year":"2025","unstructured":"Fan, L., Qiu, Z., Deng, Q., Guo, T. & Rong, L. Modeling SARS-CoV-2 infection dynamics: insights into viral clearance and immune synergy. Bull. Math. Biol. 87, 67 (2025).","journal-title":"Bull. Math. Biol."},{"key":"183_CR49","doi-asserted-by":"crossref","unstructured":"Yang, S., Jerome, K. R., Greninger, A. L., Schiffer, J. T. & Goyal, A. Endogenously produced SARS-CoV-2 specific IgG antibodies may have a limited impact on clearing nasal shedding of virus during primary infection in humans. Viruses 13, 516 (2021).","DOI":"10.3390\/v13030516"},{"key":"183_CR50","doi-asserted-by":"crossref","unstructured":"Ghostine, R., Gharamti, M., Hassrouny, S. & Hoteit, I. Mathematical modeling of immune responses against SARS-CoV-2 using an ensemble Kalman filter. Mathematics 9, 2427 (2021).","DOI":"10.3390\/math9192427"},{"key":"183_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10441-022-09447-1","volume":"70","author":"A Danchin","year":"2022","unstructured":"Danchin, A., Pagani-Azizi, O., Turinici, G. & Yahiaoui, G. COVID-19 adaptive humoral immunity models: weakly neutralizing versus antibody-disease enhancement scenarios. Acta Biotheor. 70, 23 (2022).","journal-title":"Acta Biotheor."},{"key":"183_CR52","doi-asserted-by":"crossref","unstructured":"Miroshnichenko, M. I., Kolpakov, F. A. & Akberdin, I. R. A modular mathematical model of the immune response for investigating the pathogenesis of infectious diseases. Viruses 17, 589 (2025).","DOI":"10.3390\/v17050589"},{"key":"183_CR53","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1140\/epjs\/s11734-022-00435-7","volume":"231","author":"P Rana","year":"2022","unstructured":"Rana, P., Chauhan, S. & Mubayi, A. Burden of cytokines storm on prognosis of SARS-CoV-2 infection through immune response: dynamic analysis and optimal control with immunomodulatory therapy. Eur. Phys. J. Spec. Top. 231, 3297\u20133315 (2022).","journal-title":"Eur. Phys. J. Spec. Top."},{"key":"183_CR54","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/psp4.13164","volume":"13","author":"D Yamaguchi","year":"2024","unstructured":"Yamaguchi, D., Shimizu, R. & Kubota, R. Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer. CPT Pharmacometrics Syst. Pharmacol. 13, 1354\u20131365 (2024).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"183_CR55","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s42979-021-00919-8","volume":"2","author":"I Ghosh","year":"2021","unstructured":"Ghosh, I. Within host dynamics of SARS-CoV-2 in humans: modeling immune responses and antiviral treatments. SN Comput. Sci. 2, 482 (2021).","journal-title":"SN Comput. Sci."},{"key":"183_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpt.3069","volume":"115","author":"G Lingas","year":"2023","unstructured":"Lingas, G. et al. Neutralizing antibody levels as a correlate of protection against SARS-CoV-2 infection: a modeling analysis. Clin. Pharmacol. Ther. 115, 86\u201394 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"183_CR57","doi-asserted-by":"crossref","unstructured":"Dogra, P. et al. A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection. JCI Insight 8, e169860 (2023).","DOI":"10.1172\/jci.insight.169860"},{"key":"183_CR58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","volume":"38","author":"P Mukherjee","year":"2022","unstructured":"Mukherjee, P., Roy, S., Ghosh, D. & Nandi, S. K. Role of animal models in biomedical research: a review. Lab. Anim. Res. 38, 18 (2022).","journal-title":"Lab. Anim. Res."},{"key":"183_CR59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.virol.2020.07.015","volume":"550","author":"HM Dobrovolny","year":"2020","unstructured":"Dobrovolny, H. M. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2. Virology 550, 61\u201369 (2020).","journal-title":"Virology"},{"key":"183_CR60","doi-asserted-by":"crossref","unstructured":"Pinky, L., DeAguero, J. R., Remien, C. H. & Smith, A. M. How interactions during viral-viral coinfection can shape infection kinetics. Viruses 15, 1303 (2023).","DOI":"10.3390\/v15061303"},{"key":"183_CR61","doi-asserted-by":"crossref","unstructured":"Vaidya, N. K., Bloomquist, A. & Perelson, A. S. Modeling within-host dynamics of SARS-CoV-2 infection: a case study in ferrets. Viruses 13, 1635 (2021).","DOI":"10.3390\/v13081635"},{"key":"183_CR62","doi-asserted-by":"publisher","first-page":"104448","DOI":"10.1016\/j.isci.2022.104448","volume":"25","author":"A Goyal","year":"2022","unstructured":"Goyal, A., Duke, E. R., Cardozo-Ojeda, E. F. & Schiffer, J. T. Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques. iScience 25, 104448 (2022).","journal-title":"iScience"},{"key":"183_CR63","doi-asserted-by":"publisher","first-page":"202345","DOI":"10.1098\/rsos.202345","volume":"8","author":"T Rodriguez","year":"2021","unstructured":"Rodriguez, T. & Dobrovolny, H. M. Estimation of viral kinetics model parameters in young and aged SARS-CoV-2 infected macaques. R. Soc. Open Sci. 8, 202345 (2021).","journal-title":"R. Soc. Open Sci."},{"key":"183_CR64","doi-asserted-by":"publisher","first-page":"e1011231","DOI":"10.1371\/journal.ppat.1011231","volume":"19","author":"S Torii","year":"2023","unstructured":"Torii, S. et al. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. PLoS Pathog. 19, e1011231 (2023).","journal-title":"PLoS Pathog."},{"key":"183_CR65","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11538-021-00909-0","volume":"83","author":"E Mochan","year":"2021","unstructured":"Mochan, E., Sego, T. J., Gaona, L., Rial, E. & Ermentrout, G. B. Compartmental model suggests importance of innate immune response to COVID-19 infection in rhesus macaques. Bull. Math. Biol. 83, 79 (2021).","journal-title":"Bull. Math. Biol."},{"key":"183_CR66","doi-asserted-by":"publisher","first-page":"e1008785","DOI":"10.1371\/journal.pcbi.1008785","volume":"17","author":"A Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves, A. et al. SARS-CoV-2 viral dynamics in non-human primates. PLoS Comput. Biol. 17, e1008785 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"183_CR67","doi-asserted-by":"crossref","unstructured":"Alexandre, M. et al. Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. Elife 11, e75427 (2022).","DOI":"10.7554\/eLife.75427"},{"key":"183_CR68","doi-asserted-by":"publisher","first-page":"1426016","DOI":"10.3389\/fimmu.2024.1426016","volume":"15","author":"C Byrne","year":"2024","unstructured":"Byrne, C. & Schiffer, J. T. Ensemble modeling of SARS-CoV-2 immune dynamics in immunologically naive rhesus macaques predicts that potent, early innate immune responses drive viral elimination. Front. Immunol. 15, 1426016 (2024).","journal-title":"Front. Immunol."},{"key":"183_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12692","volume":"285","author":"AM Smith","year":"2018","unstructured":"Smith, A. M. Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling. Immunol. Rev. 285, 97\u2013112 (2018).","journal-title":"Immunol. Rev."},{"key":"183_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198005","volume":"285","author":"X Zhu","year":"2020","unstructured":"Zhu, X. et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 285, 198005 (2020).","journal-title":"Virus Res."},{"key":"183_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcv.2016.04.019","volume":"80","author":"MC Scotta","year":"2016","unstructured":"Scotta, M. C. et al. Respiratory viral coinfection and disease severity in children: a systematic review and meta-analysis. J. Clin. Virol. 80, 45\u201356 (2016).","journal-title":"J. Clin. Virol."},{"key":"183_CR72","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7150\/ijms.50133","volume":"18","author":"F Illanes-Alvarez","year":"2021","unstructured":"Illanes-Alvarez, F., Marquez-Ruiz, D., Marquez-Coello, M., Cuesta-Sancho, S. & Giron-Gonzalez, J. A. Similarities and differences between HIV and SARS-CoV-2. Int. J. Med. Sci. 18, 846\u2013851 (2021).","journal-title":"Int. J. Med. Sci."},{"key":"183_CR73","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Wu, H., Cheng, H. & Lou, J. Model selection and identifiability analysis of HIV and SARS-CoV-2 co-infection model with drug therapy. Commun. Nonlinear Sci. Num. Simul. 126, 107501 (2023).","DOI":"10.1016\/j.cnsns.2023.107501"},{"key":"183_CR74","doi-asserted-by":"publisher","first-page":"e1011680","DOI":"10.1371\/journal.ppat.1011680","volume":"20","author":"T Phan","year":"2024","unstructured":"Phan, T. et al. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. PLoS Pathog. 20, e1011680 (2024).","journal-title":"PLoS Pathog."},{"key":"183_CR75","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/jmv.26098","volume":"92","author":"L Pinky","year":"2020","unstructured":"Pinky, L. & Dobrovolny, H. M. SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial?. J. Med. Virol. 92, 2623\u20132630 (2020).","journal-title":"J. Med. Virol."},{"key":"183_CR76","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.arcontrol.2021.05.001","volume":"52","author":"P Abuin","year":"2021","unstructured":"Abuin, P., Anderson, A., Ferramosca, A., Hernandez-Vargas, E. A. & Gonzalez, A. H. Dynamical characterization of antiviral effects in COVID-19. Annu. Rev. Control 52, 587\u2013601 (2021).","journal-title":"Annu. Rev. Control"},{"key":"183_CR77","doi-asserted-by":"crossref","unstructured":"Goyal, A., Cardozo-Ojeda, E. F. & Schiffer, J. T. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Sci. Adv. 6, eabc7112 (2020).","DOI":"10.1126\/sciadv.abc7112"},{"key":"183_CR78","doi-asserted-by":"crossref","unstructured":"Sadria, M. & Layton, A. T. Modeling within-host SARS-CoV-2 infection dynamics and potential treatments. Viruses 13, 1141 (2021).","DOI":"10.3390\/v13061141"},{"key":"183_CR79","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1111\/bcp.14718","volume":"87","author":"K Patel","year":"2020","unstructured":"Patel, K. et al. Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: an example in SARS-CoV-2. Br. J. Clin. Pharmacol. 87, 3425\u20133438 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"183_CR80","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/jac\/dkac048","volume":"77","author":"G Lingas","year":"2022","unstructured":"Lingas, G. et al. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. J. Antimicrob. Chemother. 77, 1404\u20131412 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"183_CR81","doi-asserted-by":"crossref","unstructured":"Yarnvitayalert, P. & Saleewong, T. Mathematical modeling of andrographolide therapy effects and immune response in in vivo dynamics of SARS-CoV-2 infection. Viruses 17, 891 (2025).","DOI":"10.3390\/v17070891"},{"key":"183_CR82","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00285-022-01849-6","volume":"86","author":"I Al-Darabsah","year":"2023","unstructured":"Al-Darabsah, I., Liao, K. L. & Portet, S. A simple in-host model for COVID-19 with treatments: model prediction and calibration. J. Math. Biol. 86, 20 (2023).","journal-title":"J. Math. Biol."},{"key":"183_CR83","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.aej.2020.12.011","volume":"60","author":"B Chhetri","year":"2021","unstructured":"Chhetri, B. et al. Within-host mathematical modeling on crucial inflammatory mediators and drug interventions in COVID-19 identifies combination therapy to be most effective and optimal. Alex. Eng. J. 60, 2491\u20132512 (2021).","journal-title":"Alex. Eng. J."},{"key":"183_CR84","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2024.0536","volume":"21","author":"L Schuh","year":"2024","unstructured":"Schuh, L. et al. Within-host dynamics of antiviral treatment with remdesivir for SARS-CoV-2 infection. J. R. Soc. Interface 21, 20240536 (2024).","journal-title":"J. R. Soc. Interface"},{"key":"183_CR85","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(20)30113-4","volume":"20","author":"Y Pan","year":"2020","unstructured":"Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. & Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 20, 411\u2013412 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"183_CR86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"183_CR87","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"KK To","year":"2020","unstructured":"To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565\u2013574 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"183_CR88","doi-asserted-by":"publisher","first-page":"e3001333","DOI":"10.1371\/journal.pbio.3001333","volume":"19","author":"SM Kissler","year":"2021","unstructured":"Kissler, S. M. et al. Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. PLoS Biol. 19, e3001333 (2021).","journal-title":"PLoS Biol."},{"key":"183_CR89","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e86","volume":"35","author":"JY Kim","year":"2020","unstructured":"Kim, J. Y. et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J. Korean Med. Sci. 35, e86 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"183_CR90","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S1473-3099(20)30314-5","volume":"20","author":"MM B\u00f6hmer","year":"2020","unstructured":"B\u00f6hmer, M. M. et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. Lancet Infect. Dis. 20, 920\u2013928 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"183_CR91","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","volume":"585","author":"VJ Munster","year":"2020","unstructured":"Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268\u2013272 (2020).","journal-title":"Nature"},{"key":"183_CR92","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/jmv.26601","volume":"93","author":"Y Yazdanpanah","year":"2021","unstructured":"Yazdanpanah, Y. French COVID cohort investigators and study group. Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. J. Med. Virol. 93, 2149\u20132159 (2021).","journal-title":"J. Med. Virol."},{"key":"183_CR93","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jama.2020.3204","volume":"323","author":"BE Young","year":"2020","unstructured":"Young, B. E. et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 323, 1488\u20131494 (2020).","journal-title":"JAMA"},{"key":"183_CR94","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1473-3099(20)30200-0","volume":"20","author":"FX Lescure","year":"2020","unstructured":"Lescure, F. X. et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect. Dis. 20, 697\u2013706 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"183_CR95","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","volume":"53","author":"R Zhou","year":"2020","unstructured":"Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53, 864\u2013877 e865 (2020).","journal-title":"Immunity"},{"key":"183_CR96","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMc2115596","volume":"385","author":"AY Collier","year":"2021","unstructured":"Collier, A. Y. et al. Differential kinetics of immune responses elicited by COVID-19 vaccines. N. Engl. J. Med. 385, 2010\u20132012 (2021).","journal-title":"N. Engl. J. Med."},{"key":"183_CR97","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"183_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100274","volume":"6","author":"M Peeters","year":"2021","unstructured":"Peeters, M. et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open 6, 100274 (2021).","journal-title":"ESMO Open"},{"key":"183_CR99","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00697-22","volume":"66","author":"H Mukae","year":"2022","unstructured":"Mukae, H. et al. A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob. Agents Chemother. 66, e0069722 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"183_CR100","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae, H. et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin. Infect. Dis. 76, 1403\u20131411 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"183_CR101","doi-asserted-by":"publisher","first-page":"e33024","DOI":"10.1097\/MD.0000000000033024","volume":"102","author":"H Yotsuyanagi","year":"2023","unstructured":"Yotsuyanagi, H. et al. A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). Medicine 102, e33024 (2023).","journal-title":"Medicine"},{"key":"183_CR102","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"183_CR103","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","volume":"129","author":"R Garzon","year":"2017","unstructured":"Garzon, R. et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood 129, 3165\u20133174 (2017).","journal-title":"Blood"},{"key":"183_CR104","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00430-020-00693-z","volume":"209","author":"M Han","year":"2020","unstructured":"Han, M. et al. Assessing SARS-CoV-2 RNA levels and lymphocyte\/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Med. Microbiol. Immunol. 209, 657\u2013668 (2020).","journal-title":"Med. Microbiol. Immunol."},{"key":"183_CR105","doi-asserted-by":"publisher","first-page":"m1443","DOI":"10.1136\/bmj.m1443","volume":"369","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 369, m1443 (2020).","journal-title":"BMJ"},{"key":"183_CR106","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643 (2020).","journal-title":"Nat. Med."},{"key":"183_CR107","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","volume":"22","author":"A Singanayagam","year":"2022","unstructured":"Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect. Dis. 22, 183\u2013195 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"183_CR108","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1515\/cclm-2020-0443","volume":"58","author":"A Padoan","year":"2020","unstructured":"Padoan, A., Cosma, C., Sciacovelli, L., Faggian, D. & Plebani, M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM\/IgG and antibody kinetics. Clin. Chem. Lab. Med. 58, 1081\u20131088 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"183_CR109","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"183_CR110","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"183_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa535","volume":"7","author":"A Bryan","year":"2020","unstructured":"Bryan, A. et al. SARS-CoV-2 viral load on admission is associated with 30-day mortality. Open Forum Infect. Dis. 7, ofaa535 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"183_CR112","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaci.2020.10.040","volume":"147","author":"C Cervia","year":"2021","unstructured":"Cervia, C. et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J. Allergy Clin. Immunol. 147, 545\u2013557 e549 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"183_CR113","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1038\/s41564-022-01254-1","volume":"7","author":"MC Choudhary","year":"2022","unstructured":"Choudhary, M. C. et al. Emergence of SARS-CoV-2 escape mutations during bamlanivimab therapy in a phase II randomized clinical trial. Nat. Microbiol. 7, 1906\u20131917 (2022).","journal-title":"Nat. Microbiol."},{"key":"183_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32551-2","volume":"13","author":"KW Chew","year":"2022","unstructured":"Chew, K. W. et al. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat. Commun. 13, 4931 (2022).","journal-title":"Nat. Commun."},{"key":"183_CR115","doi-asserted-by":"crossref","unstructured":"Nelson, C. E. et al. Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Sci. Immunol. 10, eabo0535 (2022).","DOI":"10.1126\/sciimmunol.abo0535"},{"key":"183_CR116","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","volume":"28","author":"B Killingley","year":"2022","unstructured":"Killingley, B. et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat. Med. 28, 1031\u20131041 (2022).","journal-title":"Nat. Med."},{"key":"183_CR117","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1126\/science.abb7015","volume":"368","author":"J Shi","year":"2020","unstructured":"Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016\u20131020 (2020).","journal-title":"Science"},{"key":"183_CR118","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","volume":"585","author":"P Maisonnasse","year":"2020","unstructured":"Maisonnasse, P. et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 585, 584\u2013587 (2020).","journal-title":"Nature"},{"key":"183_CR119","unstructured":"Karim, F. et al. HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave. Elife 10, e67397 (2021)."},{"key":"183_CR120","doi-asserted-by":"publisher","unstructured":"Karim, F. et al. Persistent SARS-CoV-2 infection and intra-host evolutionin association with advanced HIV infection. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.06.03.21258228 (2021).","DOI":"10.1101\/2021.06.03.21258228"},{"key":"183_CR121","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1128\/iai.29.2.348-355.1980","volume":"29","author":"BR Murphy","year":"1980","unstructured":"Murphy, B. R. et al. Evaluation of influenza A\/Hong Kong\/123\/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect. Immun. 29, 348\u2013355 (1980).","journal-title":"Infect. Immun."},{"key":"183_CR122","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jcv.2004.02.011","volume":"30","author":"JO Hendley","year":"2004","unstructured":"Hendley, J. O. & Gwaltney, J. M. Jr Viral titers in nasal lining fluid compared to viral titers in nasal washes during experimental rhinovirus infection. J. Clin. Virol. 30, 326\u2013328 (2004).","journal-title":"J. Clin. Virol."},{"key":"183_CR123","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2021.01.035","volume":"184","author":"PJM Brouwer","year":"2021","unstructured":"Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188\u20131200 e1119 (2021).","journal-title":"Cell"},{"key":"183_CR124","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"183_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25382-0","volume":"12","author":"R Marlin","year":"2021","unstructured":"Marlin, R. et al. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nat. Commun. 12, 5215 (2021).","journal-title":"Nat. Commun."},{"key":"183_CR126","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","volume":"71","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"183_CR127","doi-asserted-by":"crossref","unstructured":"Vetter, P. et al. Daily viral kinetics and innate and adaptive immune response assessment in COVID-19: a case series. mSphere 5, e00827-20 (2020).","DOI":"10.1128\/mSphere.00827-20"},{"key":"183_CR128","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273\u2013276 (2020).","journal-title":"Nature"},{"key":"183_CR129","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin, C. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71, 762\u2013768 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"183_CR130","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","volume":"22","author":"F Ader","year":"2022","unstructured":"Ader, F. et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 22, 209\u2013221 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"183_CR131","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1126\/science.abb7314","volume":"368","author":"B Rockx","year":"2020","unstructured":"Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012\u20131015 (2020).","journal-title":"Science"},{"key":"183_CR132","doi-asserted-by":"crossref","unstructured":"Jones, T. C. et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 373, eabi5273 (2021).","DOI":"10.1126\/science.abi5273"},{"key":"183_CR133","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijid.2020.04.083","volume":"95","author":"SE Kim","year":"2020","unstructured":"Kim, S. E. et al. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. Int. J. Infect. Dis. 95, 441\u2013443 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"183_CR134","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.014","volume":"81","author":"G Lui","year":"2020","unstructured":"Lui, G. et al. Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19. J. Infect. 81, 318\u2013356 (2020).","journal-title":"J. Infect."},{"key":"183_CR135","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","volume":"26","author":"I Thevarajan","year":"2020","unstructured":"Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 26, 453\u2013455 (2020).","journal-title":"Nat. Med."},{"key":"183_CR136","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","volume":"382","author":"L Zou","year":"2020","unstructured":"Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177\u20131179 (2020).","journal-title":"N. Engl. J. Med."},{"key":"183_CR137","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jmii.2020.03.032","volume":"53","author":"CY Cheng","year":"2020","unstructured":"Cheng, C. Y. et al. Lopinavir\/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J. Microbiol. Immunol. Infect. 53, 488\u2013492 (2020).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"183_CR138","doi-asserted-by":"publisher","first-page":"e0243597","DOI":"10.1371\/journal.pone.0243597","volume":"15","author":"H Kawasuji","year":"2020","unstructured":"Kawasuji, H. et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS ONE 15, e0243597 (2020).","journal-title":"PLoS ONE"},{"key":"183_CR139","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e195","volume":"35","author":"JG Yoon","year":"2020","unstructured":"Yoon, J. G. et al. Clinical significance of a high SARS-CoV-2 viral load in the saliva. J. Korean Med. Sci. 35, e195 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"183_CR140","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.3201\/eid2610.202449","volume":"26","author":"MS Han","year":"2020","unstructured":"Han, M. S. et al. Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea. Emerg. Infect. Dis. 26, 2497\u20132499 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"183_CR141","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e142","volume":"35","author":"ES Kim","year":"2020","unstructured":"Kim, E. S. et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J. Korean Med. Sci. 35, e142 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"183_CR142","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMc1511695","volume":"375","author":"MD Oh","year":"2016","unstructured":"Oh, M. D. et al. Viral load kinetics of MERS coronavirus infection. N. Engl. J. Med. 375, 1303\u20131305 (2016).","journal-title":"N. Engl. J. Med."},{"key":"183_CR143","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","volume":"361","author":"JS Peiris","year":"2003","unstructured":"Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767\u20131772 (2003).","journal-title":"Lancet"},{"key":"183_CR144","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3201\/eid2504.181595","volume":"25","author":"HM Al-Abdely","year":"2019","unstructured":"Al-Abdely, H. M. et al. Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. Emerg. Infect. Dis. 25, 753\u2013766 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"183_CR145","doi-asserted-by":"crossref","unstructured":"Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221-18 (2018).","DOI":"10.1128\/mBio.00221-18"},{"key":"183_CR146","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","volume":"73","author":"M Martinot","year":"2021","unstructured":"Martinot, M. et al. Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin. Infect. Dis. 73, e1762\u2013e1765 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"183_CR147","doi-asserted-by":"publisher","first-page":"e1009929","DOI":"10.1371\/journal.ppat.1009929","volume":"17","author":"AM Szemiel","year":"2021","unstructured":"Szemiel, A. M. et al. In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 17, e1009929 (2021).","journal-title":"PLoS Pathog."},{"key":"183_CR148","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.aml.2009.06.004","volume":"22","author":"G Huang","year":"2009","unstructured":"Huang, G., Ma, W. & Takeuchi, Y. Global properties for virus dynamics model with Beddington\u2013DeAngelis functional response. Appl. Math. Lett. 22, 1690\u20131693 (2009).","journal-title":"Appl. Math. Lett."},{"key":"183_CR149","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1128\/jvi.68.5.2898-2905.1994","volume":"68","author":"R Pearce-Pratt","year":"1994","unstructured":"Pearce-Pratt, R., Malamud, D. & Phillips, D. M. Role of the cytoskeleton in cell-to-cell transmission of human immunodeficiency virus. J. Virol. 68, 2898\u20132905 (1994).","journal-title":"J. Virol."},{"key":"183_CR150","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582\u20131586 (1996).","journal-title":"Science"},{"key":"183_CR151","doi-asserted-by":"publisher","unstructured":"Peacock, T. P. et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.12.31.474653 (2022).","DOI":"10.1101\/2021.12.31.474653"}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00183-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:03:37Z","timestamp":1773399817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00183-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["183"],"URL":"https:\/\/doi.org\/10.1038\/s44298-026-00183-8","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}